{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:29:51Z","timestamp":1786336191506,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16147-3","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:55:37Z","timestamp":1780534537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC)"],"prefix":"10.1186","volume":"26","author":[{"given":"Rosa","family":"Tambaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Calvanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Formisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Buonerba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sabbatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Chiara","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Passarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jole","family":"Ventriglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Lobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Limongello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Lamia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florinda","family":"Feroce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"16147_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859\u201366.","journal-title":"N Engl J Med"},{"key":"16147_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74:229\u201363.","journal-title":"Cancer J Clin"},{"key":"16147_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00345-009-0383-3","volume":"27","author":"M Ploeg","year":"2009","unstructured":"Ploeg M, Aben KKH, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289\u201393.","journal-title":"World J Urol"},{"key":"16147_CR4","unstructured":"ECIS - European Cancer Information System | ECIS. - European Cancer Information System. https:\/\/ecis.jrc.ec.europa.eu\/."},{"key":"16147_CR5","unstructured":"Registro Tumori Regione Campania-Registro regionale Tumori-Regione Campania. https:\/\/www.regione.campania.it\/regione\/it\/tematiche\/registro-regionale-tumori\/registro-tumori-regione-campania."},{"key":"16147_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2011.1142","volume":"306","author":"ND Freedman","year":"2011","unstructured":"Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association Between Smoking and Risk of Bladder Cancer Among Men and Women. JAMA. 2011;306:737\u201345.","journal-title":"JAMA"},{"key":"16147_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234\u201341.","journal-title":"Eur Urol"},{"key":"16147_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","volume":"66","author":"Z Kirkali","year":"2005","unstructured":"Kirkali Z, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4\u201334.","journal-title":"Urology"},{"key":"16147_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/ncpuro0510","volume":"3","author":"C Pelucchi","year":"2006","unstructured":"Pelucchi C, Bosetti C, Negri E, Malvezzi M. La Vecchia, C. Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol. 2006;3:327\u201340.","journal-title":"Nat Clin Pract Urol"},{"key":"16147_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.3390\/ijms25031557","volume":"25","author":"E Gill","year":"2024","unstructured":"Gill E, Perks CM. Mini-Review: Current Bladder Cancer Treatment\u2014The Need for Improvement. Int J Mol Sci. 2024;25:1557.","journal-title":"Int J Mol Sci"},{"key":"16147_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.euo.2023.07.011","volume":"7","author":"M Eckstein","year":"2024","unstructured":"Eckstein M, et al. Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes. Eur Urol Oncol. 2024;7:128\u201338.","journal-title":"Eur Urol Oncol"},{"key":"16147_CR12","doi-asserted-by":"publisher","first-page":"102722","DOI":"10.1016\/j.fjurol.2024.102722","volume":"34","author":"M Roumigui\u00e9","year":"2024","unstructured":"Roumigui\u00e9 M, et al. French AFU Cancer Committee Guidelines - Update 2024\u20132026: Upper urinary tract urothelial cancer (UTUC). Fr J Urol. 2024;34:102722.","journal-title":"Fr J Urol"},{"key":"16147_CR13","doi-asserted-by":"publisher","unstructured":"Gontero P et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update Eur Urol 2024;86(6):531\u2013549. https:\/\/doi.org\/10.1016\/j.eururo.2024.07.027. Epub 17 Aug 2024.","DOI":"10.1016\/j.eururo.2024.07.027"},{"key":"16147_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2022;33:244\u201358.","journal-title":"Ann Oncol"},{"key":"16147_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline. J Urol. 2016;196:1021\u20139.","journal-title":"J Urol"},{"key":"16147_CR16","doi-asserted-by":"crossref","unstructured":"Galsky MD et al. Treatment of Patients With Metastatic Urothelial Cancer Unfit for Cisplatin-Based Chemotherapy. JCO. 2011;29:2432\u20132438.","DOI":"10.1200\/JCO.2011.34.8433"},{"key":"16147_CR17","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, et al. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. 2024;391:1773\u201386.","journal-title":"N Engl J Med"},{"key":"16147_CR18","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384:2102\u201314.","journal-title":"N Engl J Med"},{"key":"16147_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00340","author":"MD Galsky","year":"2025","unstructured":"Galsky MD, et al. Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.24.00340.","journal-title":"J Clin Oncol"},{"key":"16147_CR20","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","volume":"394","author":"Christof","year":"2026","unstructured":"Christof, Vulsteke, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder. Cancer N Engl J Med. 2026;394:1257\u201369. https:\/\/doi.org\/10.1056\/NEJMoa2511674.","journal-title":"Cancer N Engl J Med"},{"key":"16147_CR21","doi-asserted-by":"publisher","first-page":"e432054","DOI":"10.1200\/EDBK_432054","volume":"44","author":"G Hemenway","year":"2024","unstructured":"Hemenway G, et al. Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient. Am Soc Clin Oncol Educ Book. 2024;44:e432054.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"16147_CR22","doi-asserted-by":"publisher","unstructured":"TBPowles T et al. Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial Ann Oncol. 2025;36(10):1212\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.536. Epub 1 Jun 2025.","DOI":"10.1016\/j.annonc.2025.05.536"},{"key":"16147_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.juro.2015.06.115","volume":"195","author":"C Oing","year":"2016","unstructured":"Oing C, et al. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol. 2016;195:254\u201363.","journal-title":"J Urol"},{"key":"16147_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/annonc\/mdv509","volume":"27","author":"D Raggi","year":"2016","unstructured":"Raggi D, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27:49\u201361.","journal-title":"Ann Oncol"},{"key":"16147_CR25","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","volume":"27","author":"J Bellmunt","year":"2009","unstructured":"Bellmunt J, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454\u201361.","journal-title":"J Clin Oncol"},{"key":"16147_CR26","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/annonc\/mdt007","volume":"24","author":"J Bellmunt","year":"2013","unstructured":"Bellmunt J, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. ANN ONCOL. 2013;24:1466\u201372.","journal-title":"ANN ONCOL"},{"key":"16147_CR27","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376:1015\u201326.","journal-title":"N Engl J Med"},{"key":"16147_CR28","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >\u20092 years of follow-up. Ann Oncol. 2019;30:970\u20136.","journal-title":"Ann Oncol"},{"key":"16147_CR29","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1200\/JCO.2021.39.15_suppl.4532","volume":"39","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt J, et al. Pembrolizumab (pembro) versus investigator\u2019s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. JCO. 2021;39:4532\u20134532.","journal-title":"JCO"},{"key":"16147_CR30","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/cpt.857","volume":"102","author":"JM Franklin","year":"2017","unstructured":"Franklin JM, Schneeweiss S. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials? Clin Pharmacol Ther. 2017;102:924\u201333.","journal-title":"Clin Pharmacol Ther"},{"key":"16147_CR31","doi-asserted-by":"publisher","unstructured":"Francesco, Massari et al. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study Cancer Immunol Immunother 2024;73(6):106. doi: 10.1007\/shttps:\/\/doi.org\/10.1007\/s00262-024-03682-w","DOI":"10.1007\/s00262-024-03682-w"},{"issue":"9","key":"16147_CR32","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1007\/s00262-023-03469-5","volume":"72","author":"Matteo","year":"2023","unstructured":"Matteo, Santoni, et al. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study. Cancer Immunol Immunother. 2023;72(9):2961\u201370. https:\/\/doi.org\/10.1007\/s00262-023-03469-5. Epub 2023 May 29.","journal-title":"Cancer Immunol Immunother"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16147-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16147-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16147-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:02:35Z","timestamp":1786334555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16147-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16147"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16147-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8651439\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d of Naples (registration number 32\/22 oss, 19 Oct 2022).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"956"}}